Sarah Lofgren is part of a team of researchers conducting a trial of hydroxychloroquine. Working out of the University of Minnesota, the team is providing the drug to First Responders to assess the impact in preventing the onset of COVID-19 as well as the drug’s ability to mitigate the more severe symptoms of the disease.
Among the topics of discussion are:
The impact of anecdotal evidence of hydroxychloroquine’s
useage around the world.
Does a pandemic offer an excuse to relax drug approval protocols?
Why use First Responders in a hydroxychloroquine trial?
Can therapies like hydroxychloroquine provide enough breathing space
to get America back to work?